# Mainz Biomed's (NASDAQ: MYNZ) Cutting-Edge Colorectal Cancer Test Applies For FDA Breakthrough Status

By Johnny Rice, Benzinga

![](https://public.newsdirect.com/224803617/V6lJq577.png)

Mainz Biomed (NASDAQ: MYNZ) has taken a significant step forward in the fight against colorectal cancer with its application to the FDA for breakthrough device designation for its colorectal cancer test. This innovative screening test could revolutionize how we detect one of the most prevalent and deadly cancers worldwide.

At its core, the test combines traditional fecal immunochemical testing with cutting-edge mRNA biomarker analysis, all enhanced by advanced AI algorithms. It's a sophisticated approach that aims to dramatically improve early detection rates for both colorectal cancer and precancerous lesions.

The numbers coming out of clinical trials are truly promising. In a study involving 295 participants across 21 U.S. gastroenterology centers, the test showed a 97% sensitivity for colorectal cancer and an 88% sensitivity for advanced precancerous lesions. These figures, coupled with a 93% overall specificity, suggest a significant improvement over current screening methods.

Mainz Biomed's CEO, Guido Baechler, emphasizes the test's potential impact, stating that the next-generation test has shown a significant improvement in sensitivity for advanced adenomas and high-grade dysplasias. This level of accuracy could be game-changing, potentially catching cancer and precancerous growths at much earlier, more treatable stages.

However, what sets this test apart isn't just its accuracy but also its accessibility. Mainz Biomed is taking a decentralized approach, partnering with third-party laboratories to make the test more widely available. This strategy could be particularly beneficial for underserved communities where access to high-quality cancer screening has often been limited.

If granted breakthrough device designation by the FDA, this test could see an expedited approval process, bringing it to patients sooner. The implications are significant: earlier and more accurate detection could lead to more timely interventions, potentially saving countless lives.

Even as the FDA's decision is pending, this test potentially represents a beacon of hope in the ongoing battle against colorectal cancer. By combining innovative biotechnology with AI, Mainz Biomed is pushing the boundaries of what's possible in cancer detection.

While it's important to temper excitement with caution until a full FDA review, this development undoubtedly marks a significant step forward. It serves as a powerful reminder of the ongoing progress in medical science and the potential for new technologies to make a real difference in people's lives.

Featured photo by Tung Nguyen from Pixabay.

Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders.

This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.

Contact DetailsBenzinga

+1 877-440-9464

info@benzinga.com

Company Websitehttp://www.benzinga.com

View source version on newsdirect.com: https://newsdirect.com/news/mainz-biomeds-nasdaq-mynz-cutting-edge-colorectal-cancer-test-applies-for-fda-breakthrough-status-224803617 

[Original/Source Press Release](https://newsdirect.com/news/mainz-biomeds-nasdaq-mynz-cutting-edge-colorectal-cancer-test-applies-for-fda-breakthrough-status-224803617) 

[Newsramp.com TLDR](https://newsramp.com/None) 